Cardioselective β1‑Selective Beta‑Blockers: Evidence‑Based Recommendations

Agents Demonstrating β1‑Selectivity (ACC/AHA Guidelines)

Metoprolol is a β1‑selective blocker without intrinsic sympathomimetic activity; typical oral dosing for angina is 50–200 mg twice daily【1】【2】.
Atenolol is a β1‑selective blocker without intrinsic sympathomimetic activity; usual oral dose is 50–200 mg once daily【1】【2】.
Acebutolol is a β1‑selective blocker with partial agonist activity; recommended dose is 200–600 mg twice daily【1】【2】.
Betaxolol is a β1‑selective blocker without intrinsic sympathomimetic activity; standard dose is 10–20 mg once daily【1】【2】.
Bisoprolol is a β1‑selective blocker without intrinsic sympathomimetic activity; typical dose is 10 mg once daily【1】【2】.
Esmolol is an intravenous β1‑selective blocker without intrinsic sympathomimetic activity; infusion rate is 50–300 µg/kg/min【1】【2】.

Bisoprolol and nebivolol exhibit the highest β1‑selectivity among available beta‑blockers, making them the most cardioselective agents in the class【1】【2】.

Propranolol, nadolol, timolol, labetalol, pindolol, and carvedilol block both β1 and β2 receptors and are therefore non‑cardioselective【1】【2】.

Cardioselective β‑blockers are preferred in patients with bronchospastic airway disease because they produce less bronchospasm than non‑selective agents, although bronchospasm may still occur at higher doses【1】【2】【3】.
When beta‑blocker intolerance is a concern, clinicians should initially choose a short‑acting β1‑specific drug such as metoprolol or esmolol【1】【2】【3】.
In patients with mild wheezing or a history of chronic obstructive pulmonary disease, a reduced dose of a short‑acting cardioselective agent (e.g., 12.5 mg oral metoprolol) is recommended rather than complete avoidance【1】【2】【3】.

Beta‑blockers lacking intrinsic sympathomimetic activity are preferred in the management of acute coronary syndrome【1】【2】【3】.

The American College of Cardiology notes that bisoprolol and nebivolol demonstrate the highest degree of β1-selectivity among the beta-blockers listed, with nebivolol having a greater degree of selectivity for β1-adrenergic receptors than other agents in this class, followed by bisoprolol and metoprolol succinate, while carvedilol is non-cardioselective as it blocks β1, β2, and α1 receptors 4
The American Heart Association guidelines recommend short-acting cardioselective β1-selective beta-blockers such as metoprolol or bisoprolol without intrinsic sympathomimetic activity for acute coronary syndromes 5

Carvedilol is a combined alpha- and beta-receptor blocker that blocks β1, β2, and α1 adrenergic receptors, making it non-cardioselective, and the α1-blockade provides more potent BP-lowering effects than β1-selective agents, which may be advantageous in patients with ACS and severe hypertension 4, 5
Cardioselective beta-blockers (nebivolol, bisoprolol, metoprolol) are preferred in patients with bronchospastic airway disease requiring a beta-blocker, as several meta-analyses concluded that cardioselective β-blockers do not produce clinically significant adverse respiratory effects in patients with chronic obstructive pulmonary disease 4, 5

The European Society of Cardiology recommends nebivolol for superior metabolic effects compared to atenolol and metoprolol, particularly in patients with metabolic syndrome or diabetes risk 6
Nebivolol does not worsen glucose tolerance even when combined with hydrochlorothiazide, whereas traditional beta-blockers increase diabetes risk 6